![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas
We have created a double mutant of the herpes simplex virus (HSV) type 1 (termed G207) with favourable properties for treating human malignant brain tumours: replication–competence in glioblastoma cells (and o...
-
Chapter
Development of Oncolytic Replication-Competent Herpes Simplex Virus Vectors
Oncolytic virus therapy is a promising new strategy for treating cancer that involves replication-competent virus vectors that can replicate in situ in tumor cells, exhibit oncolytic activity by direct cytocidal ...
-
Article
Open AccessTreatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta
Oncolytic herpes simplex virus (HSV) can replicate in and kill cancer cells while sparing the adjacent normal tissue. Hepatocellular carcinoma (HCC) is amongst the most common and lethal cancers, especially in...
-
Protocol
Immunohistochemistry for Tumor-Infiltrating Immune Cells After Oncolytic Virotherapy
Immunohistochemistry (IHC) is an integral laboratory staining technique, which is used for the detection of immune cells in mouse/human tissues or tumors. Oncolytic herpes simplex virus (oHSV) treatment or vir...